scholarly journals Mathematical modeling in drug discovery and development

2007 ◽  
Author(s):  
R. Miftahof ◽  
N. Akhmadeev
Keyword(s):  
Mathematical Modeling ◽  
Drug Discovery ◽  
Drug Discovery And Development

ASSESSING THE IMPACT OF PREDICTIVE BIOSIMULATION ON DRUG DISCOVERY AND DEVELOPMENT

2003 ◽  
Vol 01 (01) ◽  
pp. 169-177 ◽  
Author(s):  
SETH MICHELSON
Keyword(s):  
Mathematical Modeling ◽  
Drug Discovery ◽  
Laboratory Research ◽  
Pharmaceutical Companies ◽  
Drug Discovery And Development ◽  
Proteomic Data ◽  
Technical Advances ◽  
Potential Impact ◽  
The Impact ◽  
Major Data

Systems biology is creating a context for interpreting the vast amounts of genomic and proteomic data being produced by pharmaceutical companies in support of drug development. While major data collection efforts capitalize on technical advances in miniaturization and automation and represent an industrialization of existing laboratory research, the transition from mental models to predictive computer simulations is setting the pace for advances in this field. This article addresses current approaches to the mathematical modeling of biological systems and assesses the potential impact of predictive biosimulation on drug discovery and development.

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

The State of the Art in Anti-Malarial Drug Discovery and Development

2011 ◽  
Vol 999 (999) ◽  
pp. 1-29
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
The State ◽  
Drug Discovery And Development
Sign in / Sign up

Export Citation Format

Share Document